Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux

Metabolism: Clinical and Experimental

Volumn 62, Issue 3, 2013, Pages 446-456

  Shan, Yong Qiang ^a   Ren, Gang ^a   Wang, Yan Xiang ^a   Pang, Jing ^a   Zhao, Zhi Yun ^a   Yao, Jing ^b   You, Xue Fu ^a   Si, Shu Yi ^a   Song, Dan Qing ^a   Kong, Wei Jia ^a   Jiang, Jian Dong ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Hypoglycemic effect; Molecular docking; P glycoprotein; Pharmacokinetics

Indexed keywords

ANTIDIABETIC AGENT; BERBERINE; BERBERINE DERIVATIVE; GLUCOSE; IMBY 53; METFORMIN; MULTIDRUG RESISTANCE PROTEIN; TETRANDRINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL STRAIN CACO 2; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; UPREGULATION;

ANIMALS; BERBERINE; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CACO-2 CELLS; DIABETES MELLITUS; FEMALE; FLOW CYTOMETRY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR DYNAMICS SIMULATION; P-GLYCOPROTEIN; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RNA;

EID: 84874105176     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.09.009     Document Type: Article

References (49)

1. C.E. Taylor, and W.B. Greenough 3rd Control of diarrheal diseases Annu Rev Public Health 10 1989 221 244
2. W. Kong, J. Wei, and P. Abidi Berberine is a novel cholesterollowering drug working through a unique mechanism distinct from statins Nat Med 10 2004 1344 1351
3. W.J. Kong, J. Wei, and Z.Y. Zuo Combination of simvastatin with berberine improves the lipid-lowering efficacy Metabolism 57 2008 1029 1037
4. W. Zhao, R. Xue, and Z.X. Zhou Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis Biomed Pharmacother 62 2008 730 731
5. P. Abidi, Y. Zhou, and J.D. Jiang Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine Arterioscler Thromb Vasc Biol 25 2005 2170 2176
6. W. Kong, J. Liu, and J.D. Jiang Human low-density lipoprotein receptor gene and its regulation J Mol Med (Berl) 84 2006 29 36
7. W. Kong, H. Zhang, and D.Q. Song Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression Metabolism 58 2009 109 119
8. H. Zhang, J. Wei, and R. Xue Berberine lowers blood glucose in type 2 diabetic patients through increasing insulin receptor expression Metabolism 59 2010 285 292
9. H. Zhang, W.J. Kong, and Y.Q. Shan Protein kinase D activation stimulates the transcription of the insulin receptor gene Mol Cell Endocrinol 330 2010 25 32
10. Y.S. Lee, W.S. Kim, and K.H. Kim Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states Diabetes 55 2006 2256 2264
11. J. Yin, Z. Gao, and D. Liu Berberine improves glucose metabolism through induction of glycolysis Am J Physiol Endocrinol Metab 294 2008 E148 E156
12. N. Turner, J.Y. Li, and A. Gosby Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action Diabetes 57 2008 1414 1418
13. M.P. Sheng, Q. Sun, and H. Wang Studies on the intravenous pharmacokinetics and oral absorption of berberine HCl in beagle dogs Sin Pharmacol Bull 9 1993 64 67
14. F. Qiu, Z. Zhu, and N. Kang Isolation and identification of urinary metabolites of berberine in rats and humans Drug Metab Dispos 36 2008 2159 2165
15. B.X. Li, B.F. Yang, and X.M. Hao Study on the pharmacokinetics of berberine in single dosage and coadministration with oryzanol in rabbits and healthy volunteers Chin Pharm J 35 2000 33 35
16. W. Chen, Y.Q. Miao, and D.J. Fan Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats AAPS PharmSciTech 12 2011 705 711
17. Y.T. Liu, H.P. Hao, and H.G. Xie Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats Drug Metab Dispos 38 2010 1779 1784
18. S.M. He, C.G. Li, and J.P. Liu Disposition pathways and pharmacokinetics of herbal medicines in humans Curr Med Chem 17 2010 4072 4113
19. G.Y. Pan, G.J. Wang, and X.D. Liu The involvement of P-glycoprotein in berberine absorption Pharmacol Toxicol 91 2002 193 197
20. H.J. Maeng, H.J. Yoo, and I.W. Kim P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers J Pharm Sci 91 2002 2614 2621
21. N. Shitan, M. Tanaka, and K. Terai Human MDR1 and MRP1 recognize berberine as their transport substrate Biosci Biotechnol Biochem 71 2007 242 245
22. T. Efferth, M. Davey, and A. Olbrich Activity of drugs from traditional Chinese medicine toward sensitive and MDR1-or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells Blood Cells Mol Dis 28 2002 160 168
23. R.L. Juliano, and V. Ling A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim Biophys Acta 455 1976 152 162
24. M. Hennessy, and J.P. Spiers A primer on the mechanics of P-glycoprotein the multidrug transporter Pharmacol Res 55 2007 1 15
25. K.J. Linton, and C.F. Higgins Structure and function of ABC transporters: the ATP switch provides flexible control Pflugers Arch 453 2007 555 567
26. R.B. Wang, C.L. Kuo, and L.L. Lien Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors J Clin Pharm Ther 28 2003 203 228
27. P. Yang, D.Q. Song, and Y.H. Li Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators Bioorg Med Chem Lett 18 2008 4675 4677
28. Y.H. Li, P. Yang, and W.J. Kong Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy J Med Chem 52 2009 492 501
29. S.G. Aller, J. Yu, and A. Ward Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 323 2009 1718 1722
30. Y. Li, G. Ren, and P. Yang Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes J Transl Med 9 2011 62
31. L. Fu, Y. Liang, and L. Deng Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance Cancer Chemother Pharmacol 53 2004 349 356
32. L.W. Fu, Y.M. Zhang, and Y.J. Liang The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells Eur J Cancer 38 2002 418 426
33. Z.L. Liu, T. Hirano, and S. Tanaka Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells J Pharm Pharmacol 55 2003 1531 1537
34. H.L. Lin, T.Y. Liu, and C.W. Wu Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel Br J Cancer 81 1999 416 422
35. J.A. Sheps, S. Ralph, and Z. Zhao The ABC transporter gene family of Caenorhabditis elegans has implications for the evolutionary dynamics of multidrug resistance in eukaryotes Genome Biol 5 2004 R15
36. L. Fang, G. Zhang, and C. Li Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance J Med Chem 49 2006 932 941
37. R.F. Battisti, Y. Zhong, and L. Fang Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance Mol Pharm 4 2007 140 153
38. K. Sirisha, M.C. Shekhar, and K. Umasankar Molecular docking studies and in vitro screening of new dihydropyridine derivatives as human MRP1 inhibitors Bioorg Med Chem 19 2011 3249 3254
39. C.I. Ghanem, P.C. Gómez, and M.C. Arana Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein Biochem Pharmacol 68 2004 791 798
40. M.J. Knauer, B.L. Urquhart, and H.E. Meyer zu Schwabedissen Human skeletal muscle drug transporters determine local exposure and toxicity of statins Circ Res 106 2010 297 306
41. M. Verschraagen, C.H. Koks, and J.H. Schellens P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil Pharmacol Res 40 1999 301 306
42. D. Pal, and A.K. Mitra MDR-and CYP3A4-mediated drug-drug interactions J Neuroimmune Pharmacol 1 2006 323 339
43. X. Wu, Q. Li, and H. Xin Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study Eur J Clin Pharmacol 61 2005 567 572
44. Z. Cheng, A.F. Chen, and F. Wu 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models Bioorg Med Chem 18 2010 5915 5924
45. T. Wang, N. Wang, and H. Song Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine Eur J Pharm Sci 44 2011 127 135
46. W. Chen, D. Fan, and L. Meng Enhancing effects of chitosan and chitosan hydrochloride on intestinal absorption of berberine in rats Drug Dev Ind Pharm 38 2012 104 110
47. N.N. Song, Q.S. Li, and C.X. Liu Intestinal permeability of metformin using single-pass intestinal perfusion in rats World J Gastroenterol 12 2006 4064 4070
48. H.G. Kim, T.T. Hien, and E.H. Han Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation Br J Pharmacol 162 2011 1096 1108
49. J. Weiss, A. Sauer, and M. Herzog Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein Pharmacology 84 2009 264 270